Load, not cardio: the distinction the general advice keeps losing

The recommendation to train while losing weight is not controversial and this publication endorses reporting it. What deserves scrutiny is the mechanism usually offered alongside it. Resistance training during a substantial energy deficit does not reliably build muscle; the deficit is the binding constraint and no amount of load overcomes a large one. What it reliably does is attenuate the loss and, more consistently still, preserve strength and physical function even where mass declines. Those are different claims with different evidence behind them, and only the second is well supported.

What a DXA scan resolves

Dual-energy X-ray absorptiometry is the reference method in this field for practical rather than theoretical reasons: it is fast, the radiation dose is trivial, it is widely installed, and it reports regional as well as whole-body values. Its coefficient of variation for whole-body lean mass on a well-maintained clinical scanner with a consistent operator is on the order of one per cent, which sounds excellent until it is converted into kilograms. For a person with fifty-five kilograms of lean tissue, a one per cent coefficient of variation implies a least significant change — the smallest difference between two scans that can be distinguished from measurement noise with reasonable confidence — of roughly one and a half kilograms.

Appendicular lean mass, the arms-and-legs subtotal that is the closest DXA proxy for skeletal muscle, has a smaller absolute magnitude and a somewhat larger relative error, and the two effects roughly cancel. Regional values for a single limb are noisier again. None of this is a criticism of the instrument. It is the reason a body-composition report that changes by half a kilogram between visits has told the person nothing, and the reason the trial substudies report group means rather than individual trajectories.

Bioimpedance measures conductivity and calculates everything else

Bioelectrical impedance analysis passes a small alternating current through the body and measures the opposition to it. Lean tissue, being largely water and electrolyte, conducts; fat does not. From the measured impedance, a height term, a weight term and a set of population-derived regression equations, the device produces a fat mass figure. The impedance is measured. The body composition is computed from an equation fitted to somebody else.

The consequences are well documented. Agreement with DXA at the group level is often reasonable; agreement at the individual level is not, with limits of agreement for fat mass frequently spanning several kilograms in either direction, and the disagreement growing at higher body mass index — precisely the population of interest here.¹ Worse for our purposes, the measurement is sensitive to hydration status, recent exercise, recent meals, ambient temperature, skin moisture and time of day, all of which are changing during incretin treatment. A device that reads fat mass as a function of body water, used in a person whose body water is unstable, will report composition changes that are hydration changes. The Journal does not report BIA-derived composition changes from consumer devices, and would not treat them as evidence of anything.

The one trial that combined an agonist with supervised exercise

A Danish randomised trial remains the only controlled test of the obvious question. After an eight-week low-energy diet producing approximately thirteen kilograms of weight loss, participants were randomised for one year to supervised exercise alone, liraglutide 3.0 mg alone, both combined, or placebo.² The combination arm achieved the largest weight reduction and, more relevantly here, the most favourable composition outcome: body fat percentage fell roughly twice as much in the combination group as in either single-intervention group, and the exercise arms preserved lean mass better than the drug-alone arm.

Three qualifications belong with that result. The exercise was supervised and substantial — two group sessions and two individual sessions weekly, with a vigorous-intensity target — which is not what most people mean by adding exercise. The agent was liraglutide at 3.0 mg daily, producing considerably less weight loss than the current agents, so whether the interaction scales to a twenty per cent reduction is unknown. And the trial began after weight had already been lost, so it is a maintenance study rather than an induction study.

With those stated, it is the best evidence in the field and it points in the direction the general advice already points.

What the older-adult trials found

The closest analogue to rapid weight loss in an older, heavier population predates this drug class entirely. In a randomised trial of adults aged sixty-five and over with obesity, assigned to diet, exercise, both or a control condition for a year, the combination produced the largest improvement in physical function, and the exercise component attenuated the loss of lean mass and of bone mineral density that diet alone caused.³ Diet alone improved function too — carrying less mass helps — but by less, and at a measurable skeletal cost.

That trial is the template for how the question should be asked in this class: randomise the co-intervention, measure function as a primary endpoint, measure bone, and follow for long enough for the skeleton to respond. Its population, older and heavier and losing weight quickly, resembles a large share of current incretin users far more closely than the young resistance-trained cohorts from which most consumer advice descends.

The Journal cites it frequently for that reason and notes the obvious limitation: the weight loss achieved was roughly a tenth of body mass over a year, which is half or less of what the current agents produce. Whether the protective effect of training holds at twice the rate of loss is not established.

The prescription survives scrutiny; the reasoning often does not

Two claims are routinely bundled together and only one is well supported. The weaker claim is that resistance training during pharmacological weight loss builds or maintains muscle mass. In a substantial energy deficit, training generally attenuates the loss rather than preventing it, and net accrual is unusual outside of untrained beginners and the specific controlled-feeding conditions of the trials cited earlier. The stronger claim is that training preserves strength and physical function even where mass declines, which is consistently observed and is mechanistically sensible: a large part of early strength change is neural rather than structural.

The distinction has practical consequences. Somebody training hard, eating well, and watching their DXA appendicular lean mass fall by two kilograms across nine months has not failed at anything, and may be measurably stronger than at baseline. If the expectation set for them was mass preservation, they will read a normal outcome as a failure and may respond by eating more or training in ways that suit the metric rather than the goal.

The Journal reports the training recommendation and reports what it is expected to achieve, which is function first and mass second.

How the Journal reports a body-composition figure

Four things accompany every composition number in these pages. The instrument, because DXA, magnetic resonance, bioimpedance and creatine dilution are not interchangeable and the choice frequently determines the sign of the result. The sample size of the substudy rather than of the parent trial, because the parent trial size is irrelevant to the composition finding and quoting it is misleading. The definition used — total lean mass, lean soft tissue, appendicular lean mass or fat-free mass — because these differ by several kilograms in the same person. And whether the figure is a proportion of body mass or an absolute quantity.

Where a source omits any of the four, we say so rather than guessing, and where we have had to convert between definitions we show the conversion. This is more cumbersome than the alternative and it is the only way we have found to write about this subject without producing sentences that are technically true and practically misleading.

Readers who find a figure in these pages that lacks its instrument and its sample size have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

What the testing services can and cannot tell you here

A category confusion arrives in the Journal postbag with some regularity, and it is worth addressing directly. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse the contents of a vial. They report chromatographic purity, identity by mass, sometimes peptide content, and in the case of the verification services, what they were able to establish about a supplier. None of them measures anything about a person.

A certificate stating 98.7 per cent purity for a batch supplied by WWB, SSA or KP is silent on that customer’s body composition, and a low-purity result does not explain a disappointing DXA scan. The two questions are answered by different instruments in different buildings, and conflating them produces a particular kind of dead end in which somebody spends several hundred pounds on analytical testing to investigate a clinical question.

The reverse confusion also occurs: a satisfactory laboratory panel or a favourable body-composition scan is offered as evidence that a vial contained what its label claimed. It is not evidence of that either. Compounds sold for research use only are not approved for human use, and nothing in this section should be read as advice about using them.

The next instalment in this department takes up the question that follows this one chronologically rather than logically: what happens to all of it when treatment stops. The composition of regained weight is a separate literature, it is thinner than this one, and what little exists is not encouraging.